Treatment of inhibitor patients with activated prothrombin complex concentrates.
Anti-inhibitor protease complex products have demonstrated their efficacy in controlling bleeding in non-hemophilic and hemophilic patients with inhibitors to Factor VIII and IX. Treatment programs have been identified for 1) patients who develop spontaneous, mild to moderate bleeding episodes - low dose, 30 u/Kg at 8 hour intervals; 2) surgical candidates or patients with severe bleeding and high inhibitor levels - high dose, 75-100 u/Kg at 4 to 8 hour intervals; and 3) surgical candidates with low inhibitor levels (less than 40 B.U.) - pheresis, followed by Factor VIII for 6 days, and then activated concentrates. Attempts to identify the anti-inhibitor principle in the product has led us to the conclusion that Factor X is necessary for this activity.
D000293:Adolescent; D000328:Adult; D001323:Autoantibodies; D001778:Blood Coagulation Disorders / Q000628:therapy; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005169:Factor VIII / Q000276:immunology*; D006467:Hemophilia A / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007223:Infant
D001323:Autoantibodies; D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D005169:Factor VIII